Skip to main content

24-09-2020 | Lung cancer | Video

ESMO 2020 | IONESCO trial of neoadjuvant durvalumab in NSCLC terminated early

Marie Wislez presents preliminary data from the IONESCO study evaluating the feasibility of neoadjuvant durvalumab in patients with early-stage non-small-cell lung cancer, and discusses the next steps in light of the premature closure (5:27).

Funding for independent interviews at ESMO 2020 was provided by F. Hoffmann-La Roche Ltd, Basel, Switzerland.